INBX 1H TRADE IDEA got into the box after the false break out I see it will break make an attempt to exit the box balance area once more 2:1 trade idea
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
116.58 USD
1.69 B USD
200.00 K USD
10.04 M
About Inhibrx Biosciences, Inc.
Sector
Industry
CEO
Mark Paul Lappe
Website
Headquarters
La Jolla
Founded
2024
FIGI
BBG01MS5Q9G3
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded on January 8, 2024 and is headquartered in La Jolla, CA.
Short/Long $INBX Trade IdeaAs we can see $INBX "ping pong" between is "R"=resistance and "S" =support levels
Im the case he break is support we got a high chances he will retrace to close his gap or a t least check the gap horizontal support line there is no structure in the way down but recent candela from the prior month
$INBX is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
Inhibrx is advancing a pipeline of candidates for the treatment of various rare cancers and AATD.
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of INBX is 13.34 USD — it has increased by 0.08% in the past 24 hours. Watch Inhibrx Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Inhibrx Biosciences, Inc. stocks are traded under the ticker INBX.
INBX stock has fallen by −5.79% compared to the previous week, the month change is a −2.06% fall, over the last year Inhibrx Biosciences, Inc. has showed a −61.99% decrease.
We've gathered analysts' opinions on Inhibrx Biosciences, Inc. future price: according to them, INBX price has a max estimate of 15.00 USD and a min estimate of 15.00 USD. Watch INBX chart and read a more detailed Inhibrx Biosciences, Inc. stock forecast: see what analysts think of Inhibrx Biosciences, Inc. and suggest that you do with its stocks.
INBX reached its all-time high on Dec 18, 2020 with the price of 50.97 USD, and its all-time low was 7.67 USD and was reached on Jun 16, 2022. View more price dynamics on INBX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
INBX stock is 13.00% volatile and has beta coefficient of 0.82. Track Inhibrx Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Inhibrx Biosciences, Inc. there?
Today Inhibrx Biosciences, Inc. has the market capitalization of 193.11 M, it has decreased by −1.62% over the last week.
Yes, you can track Inhibrx Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Inhibrx Biosciences, Inc. is going to release the next earnings report on May 28, 2025. Keep track of upcoming events with our Earnings Calendar.
INBX earnings for the last quarter are −3.09 USD per share, whereas the estimation was −2.88 USD resulting in a −7.11% surprise. The estimated earnings for the next quarter are −2.83 USD per share. See more details about Inhibrx Biosciences, Inc. earnings.
Inhibrx Biosciences, Inc. revenue for the last quarter amounts to 100.00 K USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
INBX net income for the last quarter is −47.87 M USD, while the quarter before that showed −43.86 M USD of net income which accounts for −9.12% change. Track more Inhibrx Biosciences, Inc. financial stats to get the full picture.
No, INBX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 5, 2025, the company has 161 employees. See our rating of the largest employees — is Inhibrx Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Inhibrx Biosciences, Inc. EBITDA is −329.16 M USD, and current EBITDA margin is −164.58 K%. See more stats in Inhibrx Biosciences, Inc. financial statements.
Like other stocks, INBX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Inhibrx Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Inhibrx Biosciences, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Inhibrx Biosciences, Inc. stock shows the sell signal. See more of Inhibrx Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.